We have worked with hundreds of candidates and have the experience to help inform your approach and reduce project timescales by applying a parallel multiparametric evaluation approach covering specificity, functionality, safety and manufacturability.
Our full time equivalent (FTE) model provides you with a flexible way to apply the necessary expertise to your project with data guiding the best approach to select the superior drug candidate for progression to cell line development and manufacturing.
Our integrated end-to-end capabilities mean our design team can utilize information generated during developability assessment to remove any liabilities in real time and improve the developability profile of your drug, mitigating risk of major issues in the later development phases.
Abzena partners with you to deliver the right set of assays and analytics to assess the developability of your drug candidates, ensuring the candidates you take forward have reduced liabilities and a de-risked development path.
Get in touch